Targeting the glutamatergic system to counteract organophosphate poisoning: A novel therapeutic strategy

NEUROBIOLOGY OF DISEASE

卷:133

Review

Aroniadou-Anderjaska, Vassiliki^1,2  Figueiredo, Taiza H.¹  Apland, James P.³  Braga, Maria F.^1,2 

[1] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA

[2] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Psychiat, Bethesda, MD 20814 USA

[3] US Army Med Res Inst Chem Def, Neurosci Program, Aberdeen Proving Ground, MD 21010 USA

关键词: Organophosphorus compounds;    Nerve agents;    Status epilepticus;    Benzodiazepines;    LY293558;    Caramiphen;    AMPA receptor antagonists;    GluK1 receptor antagonists;    NMDA receptor antagonists;    Diazepam;    Midazolam;    Tezampanel;    Neuroprotection;   

DOI  :  10.1016/j.nbd.2019.02.017

来源: Elsevier

【 摘 要 】

One of the devastating effects of acute exposure to organophosphates, like nerve agents, is the induction of severe and prolonged status epilepticus (SE), which can cause death, or brain damage if death is prevented. Seizures after exposure are initiated by muscarinic receptor hyperstimulation-after inhibition of acetylcholinesterase by the organophosphorus agent and subsequent elevation of acetylcholine-but they are reinforced and sustained by glutamatergic hyperexcitation, which is the primary cause of brain damage. Diazepam is the FDA-approved anticonvulsant for the treatment of nerve agent-induced SE, and its replacement by midazolam is currently under consideration. However, clinical data derived from the treatment of SE of any etiology, as well as studies on the control of nerve agent-induced SE in animal models, have indicated that diazepam and midazolam control seizures only temporarily, their antiseizure efficacy is reduced as the latency of treatment from the onset of SE increases, and their neuroprotective efficacy is limited or absent. Here, we review data on the discovery of a novel anticonvulsant and neuroprotectant, LY293558, an AMPA/GluK1 receptor antagonist. Treatment of soman-exposed immature, young-adult, and aged rats with LY293558, terminates SE with limited recurrence of seizures, significantly protects from brain damage, and prevents long-term behavioral deficits, even when LY293558 is administered 1 h post-exposure. More beneficial effects and complete neuroprotection is obtained when LY293558 administration is combined with caramiphen, which antagonizes NMDA receptors. Further efficacy studies may bring the LY293558 + caramiphen combination therapy on the pathway to approval for human use.